PhaseII study investigating efficacy and safety of TFTD plus bevacizumab by RAS mutation status in patients with unresectable advanced or recurrent colorectal cancer refractory or intolerant to standard chemotherapy (JFMC51-1702-C7)
收藏NIAID Data Ecosystem2026-03-10 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2613978
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: TFTD: 35 mg/m. given orally twice daily on days 1-5 and 8-12 in a 28-day cycle,
Bevacizumab: 5 mg/kg, administered by intravenous infusion for 30 min every 2 weeks
Primary outcome(s): Disease control rate (DCR) by RAS mutation status
Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose
创建时间：
2018-01-15
